Get the Stockscreener App
115.72
0.05%
-0.06
Pre-market:
116.80
1.08
+0.93%
Veradermics Inc stock is traded at $115.72, with a volume of 580.68K.
It is down -0.05% in the last 24 hours and up +17.53% over the past month.
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
See More
Previous Close:
$115.78
Open:
$115.29
24h Volume:
580.68K
Relative Volume:
0.75
Market Cap:
$4.83B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-123.11
EPS:
-0.94
Net Cash Flow:
-
1W Performance:
+6.48%
1M Performance:
+17.53%
6M Performance:
+82.26%
1Y Performance:
+0.00%
1-Day Range:
$111.51
$117.91
1-Week Range:
$104.54
$122.00
52-Week Range:
$32.00
$131.24
Veradermics Inc Stock (MANE) Company Profile
Name
Veradermics Inc
Sector
Industry
Phone
228.372.3376
Address
470 JAMES STREET, NEW HAVEN
Compare MANE vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MANE
Veradermics Inc
|
115.72 | 4.83B | 0 | 0 | 0 | -0.94 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Veradermics Inc Stock (MANE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-02-26 | Initiated | Citigroup | Buy |
| Mar-02-26 | Initiated | Jefferies | Buy |
| Mar-02-26 | Initiated | Leerink Partners | Outperform |
Veradermics Inc Stock (MANE) Latest News
Veradermics (NYSE:MANE) Trading 6.1% HigherWhat's Next? - MarketBeat
Novo eyes hair-loss market amid plans to diversify (NVO:NYSE) - Seeking Alpha
Veradermics, Incorporated (NYSE:MANE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic - Yahoo Finance
Citi Keeps Their Buy Rating on Veradermics, Incorporated (MANE) - theglobeandmail.com
Veradermics at Cantor healthcare conference: hair-loss market in focus By Investing.com - Investing.com Canada
Veradermics at Cantor healthcare conference: hair-loss market in focus - Investing.com
Veradermics at citigroup summit: oral hair-loss drug nears key data - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Wellington Management Group LLP Buys Shares of 68,531 Veradermics, Incorporated $MANE - MarketBeat
Veradermics (MANE) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Seven Fleet Capital Management LP Purchases Shares of 80,000 Veradermics, Incorporated $MANE - MarketBeat
Hollander David Receives 9,650 Shares and 19,300 Derivative Securities from Veradermics on September 1, 2026 - Kalkine Media
Veradermics (MANE) R&D chief receives new stock and option awards - Stock Titan
Veradermics (MANE) Stock Looks Overvalued After Its 161% Rally - Yahoo Finance
Is Veradermics (MANE) Still Undervalued After Its 161% Year To Date Run? - Yahoo Finance
Hair Loss Biotechs Emerge As Wall Street's Newest Growth Trade - Yahoo Finance
Forget GLP-1 Stocks, Baldness Drugs Are Wall Street’s Next Goldmine - Bloomberg
Veradermics, Incorporated (NYSE:MANE) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Bamco Inc. NY Purchases 169,913 Shares of Veradermics, Incorporated $MANE - MarketBeat
Why is Veradermics stock sliding today? By Investing.com - Investing.com Canada
Veradermics stock falls following insider share sale - Investing.com
Veradermics (NYSE:MANE) Director Sells 750,000 Shares - MarketBeat
Veradermics (MANE) backer exercises $0.00001 per share warrants - Stock Titan
Veradermics (NASDAQ: MANE) insider sells stock in two August trades - Stock Titan
Veradermics (MANE) R&D chief enters insider ranks with no stake - Stock Titan
Veradermics (NYSE:MANE) Stock Price Down 7.9%Here's Why - MarketBeat
Form 144 | Veradermics(MANE.US) Insider Proposes to Sell 6.37 Million in Common Stocks - Moomoo
Veradermics (MANE) affiliate plans NYSE sale via BofA Securities - Stock Titan
Veradermics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Veradermics CEO Reid Alexander Waldman disposes of common shares worth $7.24 million - Bitget
Veradermics (NYSE:MANE) Insider Timothy August Durso Sells 43,500 Shares - MarketBeat
Veradermics (NYSE:MANE) CEO Reid Alexander Waldman Sells 67,500 Shares of Stock - MarketBeat
Veradermics(MANE.US) Officer Sells US$4.69 Million in Common Stock - Moomoo
Veradermics (MANE) CTO unloads tens of thousands of shares in preset trades - Stock Titan
Veradermics (MANE) CEO sells shares under preset trading plan - Stock Titan
Veradermics (MANE) Institutional Ownership 2026 - MarketBeat
Veradermics (MANE) affiliate lines up NYSE share sale - Stock Titan
Veradermics (NYSE: MANE) holder lines up $15M stock sale - Stock Titan
Veradermics, Inc SEC Filing (Aug 17, 2026) - Stock Titan
This Insider Has Just Sold Shares In Veradermics - webull.com
Veradermics (MANE) holder SR One sells 321,749 shares, cuts stake to 4.9% - Stock Titan
John Childs Sells 100,000 Shares of Veradermics (NYSE:MANE) Stock - marketbeat.com
Planned MANE (MANE) insider common stock sale and recent IPO activity - Stock Titan
Veradermics (MANE) director-linked trusts sell 100,000 shares of common stock - Stock Titan
Veradermics (MANE) Stock Forecast and Price Target 2026 - MarketBeat
We Think Veradermics (NYSE:MANE) Can Afford To Drive Business Growth - webull.com
Citi Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $160 - Moomoo
Needham Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $164 - Moomoo
Veradermics, Inc SEC Filing (Aug 12, 2026) - Stock Titan
Veradermics: Q2 Earnings Snapshot - theheraldreview.com
Veradermics Inc Stock (MANE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):